Dec
01
2026
December 1, 2026
ISN-Cochrane Webinar: Hemodiafiltration, hemofiltration and hemodialysis for adults with kidney failure
- 11:00 CET
Hemodialysis (HD) is the most common dialysis modality used to treat people with kidney failure. This includes standard HD or convective dialysis (hemofiltration (HF), hemodiafiltration (HDF), and acetate-free biofiltration (AFB)). This study summarizes their comparative benefits and harms.
Sixty-two studies (6,897 participants) were identified. Most studies were at high or unclear risk of bias across most methodological domains. Compared with standard HD, convective dialysis likely reduces the risk of all-cause mortality (RR 0.88, 95% CI 0.80–0.96) and cardiovascular mortality (RR 0.78, 95% CI 0.66–0.92).
Learning objectives:
- Understand the benefits and harms of convective (HF, HDF, or AFB) versus diIusive (HD) dialysis modalities, or expanded HD (HDx), in adults with kidney failure
- How do the findings of this review inform clinical management of people receiving maintenance HD?
- What are the implications for future research in HD?
Further reading:
- Canaud B, Vienken J, Ash S, et al. Hemodiafiltration to address unmet medical needs ESKD patients. Clinical journal of the American Society of Nephrology. 2018;13(9):1435.
- Ronco C, Maduell F, Kalantar-Zadeh K, et al. The role of online hemodiafiltration in contemporary kidney care. Clinical Journal of the American Society of Nephrology. 2025;21(6):1061.
- Blankestijn PJ, Vernooij RW, Hockham C, et al. Effect of hemodiafiltration or hemodialysis on mortality in kidney failure. New England Journal of Medicine 2023;389(8):700-9
- Vernooij RW, Hockham C, Strippoli G, et al. Haemodiafiltration versus haemodialysis for kidney failure: an individual patient data meta-analysis of randomised controlled trials. Lancet 2024;404(10464):1742-9.
- Battaglia Y, ShroI R, Meijers B, et al. Haemodiafiltration versus high-flux haemodialysis – a Consensus Statement from the EuDial Working Group of the ERA. Nephrology Dialysis Transplantation 2025;40(8):1590-614.
- Schouten AE, Fischer F, Blankestijn PJ, et al. A health economic evaluation of the multinational, randomized controlled CONVINCE trial: cost-utility of high-dose online hemodiafiltration compared to high-flux hemodialysis. Kidney International 2025;107(4):728-39.
- Rose M, Fischer FH, Liegl G, et al. The CONVINCE randomized trial found positive effects on quality of life for patients with chronic kidney disease treated with hemodiafiltration. Kidney International. 2024;106(5):961-71.
Moderator
Edmund Chung (Australia)
Speakers
Robin Vernooij (The Netherlands)
Giovanni Strippoli (Italy)